A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).
This study is testing a personalized cancer vaccine combined with an immunotherapy drug called pembrolizumab for people with kidney cancer. Researchers want to see if adding this custom vaccine helps prevent the cancer from returning better than immunotherapy alone.
You might be able to join if you have been diagnosed with specific types of kidney cancer at a higher risk of returning, and you currently have no remaining signs of disease after your previous treatments or surgeries.
Participants will be randomly chosen to receive either the personalized cancer vaccine or a placebo, along with the standard immunotherapy drug pembrolizumab. You will be closely monitored by the study team throughout your treatment to check your health and track your progress.
This study is currently active and ongoing at medical centers in locations such as Duarte, Los Angeles, and San Francisco, California. Although it is not actively looking for new patients right now, researchers are following those already enrolled.
- 1Tests a personalized cancer vaccine made from your own tissue alongside immunotherapy.
- 2Compares the combination treatment against a placebo plus immunotherapy.
- 3Aims to help keep kidney cancer from coming back after surgery.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.